Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

55
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
55
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

47
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
47
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Vaccine Production01:23

Vaccine Production

75
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
75

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models.

Science advances·2026
Same author

OpenStride: an inexpensive, open-source force plate actometry system for quantification of rodent motor activity and behaviour.

Scientific reports·2026
Same author

A rat hepacivirus model to aid hepatitis C viral vaccine development?

Journal of hepatology·2025
Same author

Angiostatin-a novel SARS-CoV-2 inhibitor and biomarker underlying COVID-19 pathophysiology.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Discovery of Novel Pyrido[2,3-b]Pyrazine Human Cytomegalovirus Polymerase Inhibitors with Broad Spectrum Antiherpetic Activity and Reduced hERG Inhibition.

ChemMedChem·2024
Same author

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

Trials·2024

Related Experiment Video

Updated: Apr 11, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Progress towards a hepatitis C virus vaccine.

Lok Man John Law1, Abdolamir Landi1, Wendy C Magee1

  • 1Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton T6G 2E1, Canada.

Emerging Microbes & Infections
|June 4, 2015
PubMed
Summary
This summary is machine-generated.

New hepatitis C virus (HCV) drugs offer cures but high costs limit access. Developing effective prophylactic and therapeutic HCV vaccines is crucial for global control and preventing new infections.

Keywords:
HCVhepatitisinfectionprophylactictherapeuticvaccine

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Experiment Videos

Last Updated: Apr 11, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Hepatitis C virus (HCV) poses a significant global health burden with approximately 170 million carriers.
  • Emerging antiviral drugs promise high cure rates but face challenges including cost, drug resistance, and limited efficacy against diverse HCV genotypes.
  • These limitations necessitate alternative strategies for HCV control, including vaccination.

Purpose of the Study:

  • To review the current status and rationale for developing prophylactic and therapeutic vaccines against the hepatitis C virus.
  • To assess the potential of vaccines in controlling the global HCV epidemic and aiding treatment.

Main Methods:

  • Review of existing literature on HCV vaccine candidates.
  • Analysis of immune correlates of protection against HCV.
  • Evaluation of immunogenicity and protective efficacy data from preclinical and clinical studies.

Main Results:

  • Recent advances in understanding immune responses have fostered optimism for effective HCV vaccine development.
  • Various HCV vaccine candidates have demonstrated immunogenicity and protective efficacy in animal models.
  • The focus is on eliciting cross-neutralizing antibodies and broad cellular immune responses against diverse HCV genotypes.

Conclusions:

  • Despite challenges with new antiviral therapies, prophylactic and therapeutic vaccines represent a viable strategy for global HCV control.
  • Continued research and development of HCV vaccines are essential to reduce the burden of infection and prevent new cases.
  • Optimism for successful HCV vaccine development is supported by recent scientific progress and promising preclinical data.